K Bruins Slot1, V Murray, G Boysen, E Berge. 1. Department of Internal Medicine, Ullevaal University Hospital, Oslo, Norway. karsten.bruins.slot@medisin.uio.no
Abstract
OBJECTIVE: We wanted to describe the use of thrombolytic treatment for stroke in Scandinavia, to assess stroke doctors' opinions on this treatment, to identify barriers against treatment, and to suggest improvements to overcome these barriers. METHODS: We sent questionnaires to 493 Scandinavian doctors, who were involved in acute stroke care. RESULTS: We received 453 (92%) completed questionnaires. Overall, 1.9% (range per hospital 0-13.9%) of patients received thrombolytic treatment. A majority (94%) of the respondents was convinced of the beneficial effects of thrombolytic treatment and many (85%) felt that its risks were acceptable. Main barriers were: unawareness of stroke symptoms among patients (82%) and their failure to respond adequately (54%); ambulance services not triaging acute stroke as urgent (23%); and insufficient in-hospital routines (15%). The respondents suggested that the following measures should be prioritized to increase the treatment's use: educational programmes to improve public awareness on stroke and how to respond (96%); education of in-hospital (88%) and prehospital (76%) medical staff. CONCLUSIONS: A large majority of Scandinavian doctors regard thrombolytic treatment for stroke as beneficial, yet its implementation in clinical practice has so far been poor. Our survey identified important barriers and potential measures that could increase its future use. (c) 2009 The Authors Journal compilation (c) 2009 Blackwell Munksgaard.
OBJECTIVE: We wanted to describe the use of thrombolytic treatment for stroke in Scandinavia, to assess stroke doctors' opinions on this treatment, to identify barriers against treatment, and to suggest improvements to overcome these barriers. METHODS: We sent questionnaires to 493 Scandinavian doctors, who were involved in acute stroke care. RESULTS: We received 453 (92%) completed questionnaires. Overall, 1.9% (range per hospital 0-13.9%) of patients received thrombolytic treatment. A majority (94%) of the respondents was convinced of the beneficial effects of thrombolytic treatment and many (85%) felt that its risks were acceptable. Main barriers were: unawareness of stroke symptoms among patients (82%) and their failure to respond adequately (54%); ambulance services not triaging acute stroke as urgent (23%); and insufficient in-hospital routines (15%). The respondents suggested that the following measures should be prioritized to increase the treatment's use: educational programmes to improve public awareness on stroke and how to respond (96%); education of in-hospital (88%) and prehospital (76%) medical staff. CONCLUSIONS: A large majority of Scandinavian doctors regard thrombolytic treatment for stroke as beneficial, yet its implementation in clinical practice has so far been poor. Our survey identified important barriers and potential measures that could increase its future use. (c) 2009 The Authors Journal compilation (c) 2009 Blackwell Munksgaard.
Authors: Leonard Baatiema; Ama de-Graft Aikins; Adem Sav; George Mnatzaganian; Carina K Y Chan; Shawn Somerset Journal: BMJ Open Date: 2017-04-27 Impact factor: 2.692
Authors: Leonard Baatiema; Michael E Otim; George Mnatzaganian; Ama de-Graft Aikins; Judith Coombes; Shawn Somerset Journal: Implement Sci Date: 2017-06-05 Impact factor: 7.327
Authors: E-I Ruuskanen; M Laihosalo; Je Kettunen; H Losoi; L Nurmi; A-M Koivisto; P Dastidar; J Ollikainen; M Jehkonen Journal: J Cent Nerv Syst Dis Date: 2010-12-22
Authors: Stephen Morris; Rachael M Hunter; Angus I G Ramsay; Ruth Boaden; Christopher McKevitt; Catherine Perry; Nanik Pursani; Anthony G Rudd; Lee H Schwamm; Simon J Turner; Pippa J Tyrrell; Charles D A Wolfe; Naomi J Fulop Journal: BMJ Date: 2014-08-05
Authors: Naomi J Fulop; Angus I G Ramsay; Catherine Perry; Ruth J Boaden; Christopher McKevitt; Anthony G Rudd; Simon J Turner; Pippa J Tyrrell; Charles D A Wolfe; Stephen Morris Journal: Implement Sci Date: 2016-06-03 Impact factor: 7.327